Protalix BioTherapeutics (NYSE:PLX) Upgraded to “Strong-Buy” at StockNews.com

Protalix BioTherapeutics (NYSE:PLX) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday.

Separately, HC Wainwright raised their price objective on Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 3rd.

Protalix BioTherapeutics Stock Down 0.9 %

Shares of NYSE PLX traded down $0.02 during midday trading on Wednesday, reaching $2.24. 447,749 shares of the company’s stock traded hands, compared to its average volume of 423,108. The stock’s 50 day simple moving average is $2.38 and its 200-day simple moving average is $1.69. The company has a market cap of $164.94 million, a price-to-earnings ratio of -17.23 and a beta of 0.72. Protalix BioTherapeutics has a one year low of $0.82 and a one year high of $2.76.

Institutional Investors Weigh In On Protalix BioTherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP increased its holdings in shares of Protalix BioTherapeutics by 8.5% during the third quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock valued at $444,000 after acquiring an additional 33,969 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Protalix BioTherapeutics in the third quarter worth $36,000. Virtu Financial LLC acquired a new stake in shares of Protalix BioTherapeutics during the third quarter worth $44,000. Sanctuary Advisors LLC purchased a new stake in shares of Protalix BioTherapeutics during the third quarter valued at $38,000. Finally, PFG Investments LLC acquired a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at $39,000. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.